Titre A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Protocole ID FRACTION-RCC (CA018-005)
ClinicalTrials.gov ID NCT02996110
Type(s) de cancer Rein
Phase Phase II
Stade Maladie avancée ou métastatique
Type étude Traitement
Médicament Nivolumab, Ipilimumab, Relatlimab
Institution CHU DE QUEBEC – UNIVERSITE LAVAL
   L'HOTEL-DIEU DE QUEBEC ET CRCEO
      11 Côte du Palais, Québec, QC, G1R 2J6
Ville Québec
Investigateur(trice) principal(e) Dr Vincent Castonguay
Coordonnateur(trice) Marilyn Savard
418-525-4444 poste 20414
Statut Actif en recrutement
Critètes d'éligibilité
  • Advanced Renal Cell Carcinoma
  • Must have at least 1 lesion with measurable disease
  • Life expectancy of at least 3 months
Critètes d'exclusion
  • Patients/subjects with suspected or known central nervous system metastases unless adequately treated
  • Patients/subjects with autoimmune disease
  • Patients/subjects who need daily oxygen therapy